{"entity":{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","aka":["Arcus Biosciences, Inc."],"tldr":"Arcus Biosciences is a United States-based biotechnology company running 4 late-stage cancer trials of Domvanalimab and Quemliclustat in gastric & gastro-oesophageal junction cancer, renal cell carcinoma and pancreatic ductal adenocarcinoma.","summary":"Arcus Biosciences, based in Hayward, the United States, is a biotechnology company. Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small-molecule and antibody combination therapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Domvanalimab and Quemliclustat in gastric & gastro-oesophageal junction cancer, renal cell carcinoma, pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT07011719 (Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma), plans to enrol 720 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.arcusbio.com"},{"label":"ClinicalTrials.gov: trials led by Arcus Biosciences","url":"https://clinicaltrials.gov/search?lead=Arcus%20Biosciences%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["gastric","rcc","pancreatic","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["domvanalimab","quemliclustat","zimberelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07011719","nct04736173","nct05329766"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hayward","country":"US","companyType":"biotech","website":"https://www.arcusbio.com","founded":2015,"stage":"public","investors":[],"funding":[]},"route":"/companies/arcus-biosciences/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/"},{"id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"trial":[{"id":"nct05024097","kind":"trial","name":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for","route":"/trials/nct05024097/"},{"id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/"},{"id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/"},{"id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07011719/"},{"id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/"}],"company":[{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/"}]}}